US FDA Balances Urgent Need For Platinum Chemotherapies Against Intas Plant’s Quality Failures

As politicians demand help for cancer-ridden constituents, the agency allows Indian plant that flunked inspection to resume exporting batches of cisplatin and carboplatin to the US, but only after passing independent 45-day batch certification reviews.

Hanging in the balance
cancer treatments hanging in the balance • Source: Shutterstock

The US Food and Drug Administration is carefully treading a line between product quality and availability by allowing imports of two oft-curative generic cancer drugs from an Indian plant to stem serious shortages that followed a disastrous inspection, but only with strict oversight reminiscent of consent decree terms.

The agency spelled out the arrangement in an unusual import alert notification letter that it posted 2 June amid an...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Manufacturing

More from Compliance